Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 112 | 7.350 |
Why?
|
| Sarcoma | 15 | 2023 | 65 | 2.850 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 22 | 1.850 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 13 | 1.600 |
Why?
|
| Bone Substitutes | 8 | 2017 | 18 | 1.580 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 6 | 1.430 |
Why?
|
| Bone Transplantation | 7 | 2017 | 184 | 1.200 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 17 | 1.080 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 41 | 0.920 |
Why?
|
| Limb Salvage | 5 | 2023 | 9 | 0.900 |
Why?
|
| Humans | 60 | 2023 | 25165 | 0.860 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3185 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 172 | 0.820 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 7 | 0.720 |
Why?
|
| Osteosarcoma | 8 | 2021 | 31 | 0.700 |
Why?
|
| Adult | 23 | 2022 | 7259 | 0.690 |
Why?
|
| Hip Joint | 2 | 2016 | 502 | 0.680 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 20 | 0.680 |
Why?
|
| Fractures, Bone | 2 | 2012 | 65 | 0.650 |
Why?
|
| Adolescent | 15 | 2021 | 2018 | 0.640 |
Why?
|
| Young Adult | 12 | 2021 | 1813 | 0.640 |
Why?
|
| Child, Preschool | 9 | 2021 | 609 | 0.640 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 2 | 0.630 |
Why?
|
| Tibia | 2 | 2010 | 207 | 0.620 |
Why?
|
| Child | 12 | 2021 | 1211 | 0.590 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3204 | 0.580 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 547 | 0.560 |
Why?
|
| Middle Aged | 21 | 2021 | 8303 | 0.550 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.540 |
Why?
|
| Male | 25 | 2021 | 13815 | 0.530 |
Why?
|
| Bone Diseases | 2 | 2017 | 21 | 0.530 |
Why?
|
| Arthrodesis | 2 | 2014 | 35 | 0.520 |
Why?
|
| Internal Fixators | 1 | 2016 | 35 | 0.520 |
Why?
|
| Foot | 1 | 2016 | 43 | 0.510 |
Why?
|
| Radiotherapy | 1 | 2016 | 28 | 0.510 |
Why?
|
| Foreign Bodies | 1 | 2016 | 26 | 0.510 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 26 | 0.510 |
Why?
|
| Acetabulum | 3 | 2016 | 221 | 0.510 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 66 | 0.490 |
Why?
|
| Female | 22 | 2021 | 14161 | 0.480 |
Why?
|
| Radius | 2 | 2014 | 31 | 0.480 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 197 | 0.460 |
Why?
|
| Tobramycin | 2 | 2005 | 9 | 0.450 |
Why?
|
| Survival Rate | 5 | 2021 | 290 | 0.440 |
Why?
|
| Biopsy | 6 | 2023 | 181 | 0.420 |
Why?
|
| Arthralgia | 2 | 2011 | 125 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 348 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 29 | 0.400 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 273 | 0.380 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 41 | 0.380 |
Why?
|
| Prognosis | 8 | 2023 | 693 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 49 | 0.370 |
Why?
|
| Allografts | 4 | 2021 | 192 | 0.370 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 4 | 0.370 |
Why?
|
| Talus | 1 | 2011 | 13 | 0.360 |
Why?
|
| Edema | 1 | 2011 | 25 | 0.360 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1672 | 0.350 |
Why?
|
| Patellar Ligament | 1 | 2010 | 37 | 0.350 |
Why?
|
| Humerus | 3 | 2005 | 100 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 544 | 0.330 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 491 | 0.330 |
Why?
|
| Femur | 4 | 2022 | 338 | 0.320 |
Why?
|
| Osteomyelitis | 3 | 2005 | 19 | 0.310 |
Why?
|
| Reoperation | 6 | 2022 | 847 | 0.290 |
Why?
|
| Bone Plates | 1 | 2008 | 42 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 52 | 0.280 |
Why?
|
| Aged | 12 | 2021 | 8448 | 0.280 |
Why?
|
| Cisplatin | 3 | 2017 | 50 | 0.270 |
Why?
|
| Osteogenesis | 1 | 2007 | 101 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 749 | 0.260 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 270 | 0.250 |
Why?
|
| Curettage | 3 | 2022 | 7 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4508 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 142 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 53 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 342 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 237 | 0.230 |
Why?
|
| Infant | 3 | 2021 | 520 | 0.230 |
Why?
|
| Margins of Excision | 2 | 2022 | 25 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 353 | 0.220 |
Why?
|
| Knee Joint | 2 | 2008 | 662 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2004 | 17 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 86 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 35 | 0.210 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 53 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 637 | 0.210 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 74 | 0.200 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 147 | 0.200 |
Why?
|
| Neutrophils | 1 | 2023 | 99 | 0.200 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 331 | 0.200 |
Why?
|
| Plasma Gases | 1 | 2022 | 1 | 0.200 |
Why?
|
| Absorbable Implants | 1 | 2002 | 26 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 193 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 5 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 572 | 0.190 |
Why?
|
| Bone Cements | 3 | 2022 | 78 | 0.190 |
Why?
|
| Vancomycin | 1 | 2002 | 50 | 0.190 |
Why?
|
| Radiography | 5 | 2015 | 566 | 0.190 |
Why?
|
| Debridement | 2 | 2012 | 88 | 0.180 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 8 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 89 | 0.180 |
Why?
|
| Myxosarcoma | 1 | 2020 | 2 | 0.180 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 1 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 510 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 173 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 17 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 150 | 0.160 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 234 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 8 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 16 | 0.160 |
Why?
|
| Dogs | 4 | 2007 | 164 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 37 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 57 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 61 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 302 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 83 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 106 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 82 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 177 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 39 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 50 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 75 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Synovectomy | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 6 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 65 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1772 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1336 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 3 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 89 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 456 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 24 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 16 | 0.120 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 365 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 96 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 32 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 130 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 163 | 0.110 |
Why?
|
| Hand Strength | 1 | 2014 | 57 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2014 | 57 | 0.110 |
Why?
|
| Risk Factors | 2 | 2022 | 2179 | 0.110 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 12 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1032 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 442 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2012 | 267 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 20 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 106 | 0.100 |
Why?
|
| Bone Cysts | 1 | 2012 | 1 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 24 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 32 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 60 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 68 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 318 | 0.100 |
Why?
|
| Animals | 5 | 2007 | 3430 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 31 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 33 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 655 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 23 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 21 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 27 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 712 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 324 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 450 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 916 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 231 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 18 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 30 | 0.070 |
Why?
|
| Injections | 1 | 2007 | 39 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 231 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1618 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 81 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 25 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 6 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 46 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 63 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 98 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 28 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2006 | 96 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 12 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 136 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 319 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 305 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 85 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 23 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 31 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 104 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 47 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 48 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 320 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 15 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 3 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 19 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 53 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 108 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 11 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 23 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 79 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 8 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 401 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2011 | 990 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 25 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 2 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 8 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 14 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 89 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 28 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 37 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 46 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 82 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 578 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 93 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 41 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 41 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 23 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 397 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 204 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 593 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 126 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 113 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 8 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 24 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 12 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 48 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 74 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 8 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 36 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 145 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 5 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 39 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 35 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 72 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 19 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 48 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 132 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 42 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 5 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 14 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 58 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 97 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 111 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 130 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 111 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 184 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 27 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 6 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 7 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 250 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 55 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 104 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 293 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 567 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 5 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 8 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 8 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 10 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 14 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 20 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 32 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 24 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 118 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 50 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 52 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 479 | 0.010 |
Why?
|